Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 12/20 | 0.36 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.33 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29318295 | 0.81 | MAPT (0.41) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL29318392 | 0.81 | MAPT (0.41) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL29303268 | 0.81 | MET (0.38) | MAPTKDM4ENSD2ALDH1A1MET | |
| SCHEMBL19531676 | 0.81 | ALDH1A1 (0.43) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL26768229 | 0.79 | MAPT (0.42) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL24930081 | 0.79 | KDM4E (0.42) | MAPTKDM4ENSD2ALDH1A1MAOA | |
| SCHEMBL26482518 | 0.79 | MAPT (0.42) | MAPTKDM4ENSD2ALDH1A1 | |
| SCHEMBL29303269 | 0.79 | CHRM1 (0.45) | KDM4EMAOAMAOB | |
| SCHEMBL29303265 | 0.79 | MAPT (0.46) | MAPTKDM4ENSD2ALDH1A1MET | |
| SCHEMBL24255521 | 0.77 | ALDH1A1 (0.43) | MAPTKDM4ENSD2ALDH1A1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-10-12 | — | — | US | disclosed |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-10-12 | — | — | US | disclosed |
| US-20230128162-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230128162-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4122926-A1 | TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi & Co., Ltd (JP) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022036177-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM2 | MAPT 3350/4885KDM4E 1209/4885NSD2 1450/4885 |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | MAPT 3982/4885KDM4E 1854/4885NSD2 681/4885 |
| US-20230128162-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE, ACE2, SARS1 | MAPT 3115/4885KDM4E 1197/4885NSD2 123/4885 |
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM3, CHRM2 | MAPT 337/4885KDM4E 2149/4885NSD2 1378/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | MAPT 2035/4885KDM4E 2019/4885NSD2 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.